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Abstract
Introduction: Recent studies have demonstrated that inactivated seasonal influenza vaccines (IIV) may elicit production of
heterosubtypic antibodies, which can neutralize avian H5N1 virus in a small proportion of subjects. We hypothesized that
prime boost regimens of live and inactivated trivalent seasonal influenza vaccines (LAIV and IIV) would enhance production
of heterosubtypic immunity and provide evidence of cross-protection against other influenza viruses.
Methods: In an open-label study, 26 adult volunteers were randomized to receive one of four vaccine regimens containing
two doses of 2009-10 seasonal influenza vaccines administered 8 (61) weeks apart: 2 doses of LAIV; 2 doses of IIV; LAIV then
IIV; IIV then LAIV. Humoral immunity assays for avian H5N1, 2009 pandemic H1N1 (pH1N1), and seasonal vaccine strains
were performed on blood collected pre-vaccine and 2 and 4 weeks later. The percentage of cytokine-producing T-cells was
compared with baseline 14 days after each dose.
Results: Subjects receiving IIV had prompt serological responses to vaccine strains. Two subjects receiving heterologous
prime boost regimens had enhanced haemagglutination inhibition (HI) and neutralization (NT) titres against pH1N1, and
one subject against avian H5N1; all three had pre-existing cross-reactive antibodies detected at baseline. Significantly
elevated titres to H5N1 and pH1N1 by neuraminidase inhibition (NI) assay were observed following LAIV-IIV administration.
Both vaccines elicited cross-reactive CD4+ T-cell responses to nucleoprotein of avian H5N1 and pH1N1. All regimens were
safe and well tolerated.
Conclusion: Neither homologous nor heterologous prime boost immunization enhanced serum HI and NT titres to 2009
pH1N1 or avian H5N1 compared to single dose vaccine. However heterologous prime-boost vaccination did lead to in vitro
evidence of cross-reactivity by NI; the significance of this finding is unclear. These data support the strategy of administering
single dose trivalent seasonal influenza vaccine at the outset of an influenza pandemic while a specific vaccine is being
developed.
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Introduction
The threat of pandemic influenza remains a major public health
concern. In recent years, several avian viruses have crossed the
species barrier and directly infected humans, presenting a possible
pandemic threat. One of these is avian influenza H5N1 virus,
which has a mortality rate of more than 50% in the 600
laboratory-confirmed human cases reported by WHO since 2003
[1]. Current seasonal trivalent influenza vaccines rely on predicted
antigens based on the previous season’s circulating viruses, and do
not allow for the sudden antigenic shift that leads to a pandemic;
moreover development of a specific vaccine against a new
pandemic virus takes time. Efforts are now focussed on the search
for a universal influenza vaccine that can confer broad and long-
lasting protection to all types of influenza.
Live, attenuated influenza vaccine (LAIV) is an intranasally
administered vaccine, designed to induce an immune response
resembling infection with wild-type influenza without causing
disease [2]. Compared to conventional intramuscular inactivated
vaccines (IIV), LAIV is believed to induce mucosal antibody
responses and cellular immunity [3]. Moreover, LAIV can induce
responses to antigenically mismatched influenza A strains [4]. It
has been well documented that heterologous prime boost
vaccination elicits high-magnitude, broad-based and long-lasting
immunity in several different animal and disease models [5] [6]
[7]. Recent work in mice, ferrets and monkeys demonstrated that a
prime boost strategy of a DNA vaccine followed by seasonal IIV
conferred protection against a range of influenza viruses by
inducing broadly neutralizing antibodies against the stem cell
region of the haemagglutinin (HA) glycoprotein [8].
We describe here a pilot feasibility study designed to test the
hypothesis that heterologous prime-boost immunization of healthy
humans with seasonal trivalent LAIV and IIV would induce
evidence of in vitro cross-protection against non-vaccine influenza
viruses such as avian H5N1 and pandemic 2009 H1N1.
Materials and Methods
Ethics Statement
The study was approved by the Walter Reed Army Institute of
Research (WRAIR) IRB (FWA00000015) and governed by ICH
GCP guidelines.
Design
This was a randomized, open-label, pilot feasibility study of four
two-dose vaccine regimens using two commercially available
trivalent seasonal influenza vaccines to compare immune respons-
es and in vitro cross-reactivity against avian H5N1 and pandemic
2009 H1N1 viruses. The protocol for this trial and supporting
CONSORT checklist are available as supporting information; see
Checklist S1 and Protocol S1.
Subjects
26 healthy U.S. citizens living in Bangkok, Thailand, aged 18–
49 years who had not received influenza vaccination (either
seasonal or 2009 pandemic H1N1) within the preceding 6 months
were recruited into the study if they tested negative for HIV and
had a normal complete blood count at screening. All subjects gave
written informed consent prior to study participation.
Location
All vaccine doses were administered at the US Embassy Medical
Unit, Bangkok, Thailand. Other clinical activities were conducted
either at the US Embassy Medical Unit, Bangkok and/or the
Department of Immunology and Medicine, AFRIMS, Bangkok.
Clinical Methods
Vaccine administration. The vaccines used were FluMistH
intranasal live, attenuated influenza virus (LAIV) vaccine (dose
0.1 mL per nostril, supplied by MedImmune, Gaithersburg, MD);
and FluzoneH inactivated influenza virus (IIV) vaccine (dose
0.5 mL intramuscularly, purchased in Thailand from Sanofi-
Pasteur). Both vaccines contained the three strains for the 2009/10
northern hemisphere season: A/South Dakota/6/2007 (H1N1)
(an A/Brisbane/59/2007-like), A/Uruguay/716/2007 (H3N2)
(an A/Brisbane/10/2007-like), and B/Brisbane/60/2008. En-
rolled subjects were allocated consecutively numbered sealed
envelopes containing one of four vaccine regimens: homologous
prime boost regimen 1 (Group 1): LAIV two doses separated by 8
weeks (67 days), n = 5; homologous prime boost regimen 2
(Group 2): IIV two doses separated by 8 weeks (67 days), n = 5;
heterologous prime boost regimen 1 (Group 3), LAIV single dose,
followed by IIV single dose 8 weeks (67 days) later, n = 8;
heterologous prime boost regimen 2 (Group 4): IIV single dose
followed by LAIV single dose 8 weeks (67 days) later, n = 8. The
randomization code was computer-generated and the key
maintained by a research nurse independent from the study team.
Sample collection. Antibody and cellular responses were
measured in blood and following nasal irrigation with 20 ml
warmed 0.9% saline two and four weeks after each vaccine dose
and compared with baseline values. Blood for serum separation
was collected in SST (Serum Separation Tube with clot activator
and gel). For peripheral blood mononuclear cells, blood was
collected in heparinized tubes and cells separated by histoplaque
using Leucosep tubes. Serum samples and peripheral blood
mononuclear cells were stored in liquid nitrogen until use. All
laboratory staff were blinded as to allocation of vaccine regimens
until the study database was locked.
Adverse event (AE) reporting. Because the current recom-
mendation for healthy adults is to receive a single dose of seasonal
trivalent influenza vaccine, and because of a lack of published data
on the safety of two doses in adults, detailed safety data was
collected for the duration of this study. All subjects were asked to
complete a Symptom Diary daily for 14 days following each dose
of vaccine. All AEs that were reported and all concomitant
medication used, whether or not attributed or related to vaccine
administration, were recorded from the time of first phlebotomy
until the end of study participation. AEs were documented
individually, not by syndrome, and classified according to
MedDRAH (the Medical Dictionary for Regulatory Activities),
which is international medical terminology developed under the
auspices of the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals for
Human Use. Each AE was described by its duration, an
assessment of causality (vaccine, coexisting disease, due to
concomitant medication, or others), relationship to vaccine (not
related, unlikely, possibly, probably, definitely), and whether
specific therapy was required. The subject and investigator made
an assessment of severity for each reported AE as follows: mild
(self-limiting or minor symptoms that did not affect activities of
daily living and did not require treatment); moderate (symptoms
that required treatment in order to carry out activities of daily
living); and severe (symptoms preventing activities of daily living
and requiring out-patient treatment).
Cross-Reactivity after Seasonal Influenza Vaccine
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Laboratory Methods
Haemagglutination inhibition (HI) assay. Sera were
treated with receptor-destroying enzyme and subsequently heat-
inactivated. The haemagglutination inhibition assay was per-
formed by WHO standard methods using 8 HA units of influenza
virus. Guinea pig red blood cells were used for seasonal influenza
viruses and 2009 pH1N1 and goose red blood cells were used for
avian influenza H5N1. Samples were tested in serial 2-fold
dilutions by starting at 1:10 dilution. The antibody titres were
defined as the reciprocal of the highest dilution of sera samples that
completely inhibits haemagglutination. Titres that were lower than
the detection limit were assigned a value of 5 for analysis of
geometric mean titre (GMT).
Neutralization (NT) assays. Influenza A (H5) pseudotyped
lentiviral particle (H5pp)-based serological assay. H5 haemagglutinin (A/
Cambodia/408008/05; clade 1) pseudotyped lentiviral particles
were obtained from HKU-Pasteur Research Center. The assay
was conducted as previously described [9]. Samples were tested in
serial 2-fold dilutions by starting at 1:20 dilution. The neutrali-
zation titre was defined as the reciprocal of the highest dilution of
sera samples that inhibited 50% infection. Samples that tested
negative at 1:10 were assigned a titre of 1:5 for analysis of
geometric mean titre (GMT).
Microneutralization assay for 2009 pH1N1. To detect
antibodies that could inhibit infection of cells with influenza virus,
microneutralization assays were performed using Madin-Darby
canine kidney (MDCK) cells. Samples were heat-inactivated
(30 min at 56uC) and serial dilutions pre-incubated with 2009
H1N1 (A/California/04/2009:100 TCID50) in 96-well plates.
After 1–2 h incubation at 37uC in a 5% CO2, the mixtures were
added to a pre-formed monolayer of MDCK cells and the plates
were incubated for another 18 hours. MDCK monolayers were
then washed with PBS and fixed in cold 80% acetone for 10 min.
The presence of viral protein was detected by ELISA using a
monoclonal antibody to the influenza A nucleoprotein (NP). The
second antibody conjugated with peroxidase was added and
incubated for another 1 h. Plates were washed, and specific
enzyme substrate added. The reactions were stopped with 1 N
sulphuric acid. The absorbance was measured at 490 nm. The
average A490 was determined for quadruplicate wells of virus-
infected (VC) and –uninfected (CC) control wells, and a
neutralizing endpoint determined by using a 50% specific signal
calculation. The endpoint titre was expressed as the reciprocal of
the highest dilution of serum with A490 value less than X, where
X= [(average A490 of VC wells) - (average A490 of CC wells)]/
2+(average A490 of CC wells). Sera, which tested negative at a
dilution of 1:20, were assigned a titre of 1:10 for analysis of GMT.
Antibody staining against H5N1 matrix 2 protein (M2e)
expressed cell line intensity. HEK 293 stably expressing
H5N1 M2e (A/Vietnam/1203/04) on the cell surface was
provided by Dr. M. Moyle (Theraclone Science, WA). Cells were
stained with a 1:10 dilution of sera samples and then detected by
florescent dye conjugated anti-human antibodies [10]. Mean
fluorescence intensity of stained cells was analyzed by flow
cytometry.
Neuraminidase inhibition (NI) assay. Sera were assayed
for antibodies against neuraminidase by a standard colorimetric
neuraminidase inhibition method [11]. Samples were tested in
serial 2-fold dilutions by starting at 1:160. The neutralization titre
was defined as the reciprocal of the highest dilution of sera samples
that inhibited 50% of neuraminidase activity. Titres that were
lower than the detection limit were assigned a value of 1:80 for
analysis of GMT.
T-cell responses. Intracellular cytokine staining (ICS) was
used to assess antigen-specific T-cell responses. Cryopreserved
PBMC (106 cells) in 200 ml of complete medium were stimulated
with either IIV (final 1/100 dilution), nucleoprotein (NP) peptide
derived from A/California/04/2009 (H1N1) (122 15–mer peptide
overlapping by 11 amino acids) or A/Vietnam/1194/2004
(H5N1) (121 15–mer peptide overlapping by 11 amino acids) at
a final concentration of each peptide of 1 mg/ml. NP is the main
viral protein recognized by cross-reactive T cells [12]. All
stimulated PBMC cultures contained 1 mg/ml of anti-CD28 and
1 mg/ml of anti-CD49. Staphylococcal enterotoxin (SEB) (4 mg/
ml) and medium were used as positive and negative controls,
respectively. After 2 h of stimulation, Golgiplug was added to
inhibit cytokine secretion and the cell cultures were further
incubated overnight. Then cells were washed and stained for CD4
and CD8. The stained cells were fixed/permeabilized and
intracellular cytokines were stained with MAbs against IFN-g
and IL-2. Finally, stained cells were analysed by four-color flow
cytometry. The samples considered positive were those in which
the percentage of cytokine-staining cells was at least twice that for
the background or in which there was a distinct population of
bright cytokine-positive cells.
Analysis of nasal wash samples. Samples were stored in
liquid nitrogen until use. IgA was purified from nasal fluid samples
using a Staphylococcus aureus superantigen-like protein 7/Agarose
column. Nasal wash purified IgA samples were assessed for
influenza reactivity in HI and neutralization assays.
Statistical analysis
This was a descriptive pilot feasibility study, designed to detect
trends in safety and immune responses that could warrant
expanded investigations of potentially promising combinations
[13] [14]. A target sample size of 5 in arms 1 and 2 (homologous
prime boost), and 8 subjects in arms 3 and 4 (heterologous prime
boost), was selected based on what is generally considered
adequate for phase I trials [15–17]. Since recruitment of subjects
was dependant on a limited number of consenting US citizens
resident in Bangkok who fulfilled eligibility criteria, there was no
stratification of enrolment based on age or gender; these and other
possible confounders can be addressed in any future large-scale
trials.
Immunological titres and other continuous data were expressed
as geometric means (GMT) and 95% confidence intervals
(95%CI), or as medians (interquartile range); differences between
vaccine groups were compared using Kruskall-Wallis and Mann-
Whitney rank sum non-parametric tests. In vivo (AE) data was
presented using counts and percentages; differences between doses
and vaccine groups were compared using Chi-squared and Fishers
exact tests.
All statistical tests were performed at the 5% significance level
and corresponding 95% confidence intervals were estimated.
Statistical analyses were performed using SPSS version 12.0 (SPSS
Inc., Chicago, IL) and Stata version 11 (College Station, TX) and
reported using CONSORT methodology [18].
Results
Between October 2009 and March 2010 twenty-six subjects
were enrolled into the study: 5 in each of Arms 1 and 2, and 8 in
each of Arms 3 and 4 (Figure 1, Table 1). None gave a prior
history of recent (within 6 months) influenza-like illness (ILI)
despite emergence of pandemic H1N1 2009 influenza in Bangkok
during the study period. This was a highly vaccinated group of
subjects, with 73% having received at least one previous influenza
Cross-Reactivity after Seasonal Influenza Vaccine
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vaccination; the median number of influenza vaccinations was 10
(IQR 10, range 0–17) of whom 21% reported experiencing 1 or
more side effects after previous vaccination.
Immunological findings
Vaccine–induced antibody responses. Post-vaccination
serum antibody titres against seasonal vaccine strains (A/H1N1,
A/H3N2 and influenza B) were generally robust following
vaccination with IIV as determined by both haemagglutination
inhibition (HI) and neuraminidase inhibition (NI) (Figures S1, S2,
S3). Increased titres were primarily generated by one dose of IIV,
whether given as prime in homologous prime-boost vaccination
(Group 2), or as prime or boost in heterologous prime-boost
vaccination (Groups 3 and 4). GMT increases of HI antibody for
H1N1, H3N2 and influenza B were, respectively: Group 2 ((from
26 to 70, 13 to 121 and 106 to 160; or 2.6-, 9.2- and 1.5-fold
increases), Group 3 (from 17 to 80, 14 to 123 and 104 to 247; or
4.8-, 8.0- and 2.4-fold increases), and Group 4 (from 20 to 67, 14
to 160 and 123 to 207; or 3.3-, 11.3- and 1.7-fold increases). IIV
did not prime for IIV (Group 2), as GMT values plateaued after
the first dose. LAIV (Group 1, 3 and 4), regardless of vaccination
schedule, was not associated with any demonstrable serum
antibody production. GMT values of IIV prime (Groups 2 and
4), compared with IIV boost (Group 3), indicated LAIV did not
prime for IIV, or that it led to serum antibody levels generated by
IIV prime (Group 4) being maintained for longer. Influenza B
antibodies were relatively high at baseline, and associated with
relatively smaller post-vaccination antibody responses after 14
days. Such an inverse correlation was also detected in some
subjects who did have high baseline serum HI titres($40) to H1N1
and H3N2. Relatively high pre-existing NI titres were detected for
A/H1N1 (GMT 280; 95%CI 205 to 382), but not A/H3N2
(GMT 80; 95%CI 80 to 80). IIV as prime or boost (Group 2, 3
and 4) increased GMT for A/H1N1 from 197 to 592, 239 to 1004
and 306 to 1025 (3–4.5 fold increase). For A/H3N2, IIV, as prime
or boost increased GMT from 80 to 265, 80 to 145 and 80 to 227
in groups 2, 3 and 4 respectively (1.8–3.3 fold increase).
Cross-reactive antibody responses. These were assessed
using HI, NT and NI assays. The induction of cross-reactive
antibodies to H5N1 or 2009 pH1N1 was independent of antibody
response to vaccine-specific strains (Figures 2 and 3; figures S1, S2,
S3). IIV did not prime for IIV (Group 2), and LAIV (Group 1, 3
and 4), regardless of schedule, did not generate serum antibody
production, nor prime for IIV (Group 3).
H5N1.. At baseline 2 of 26 (8%) subjects had cross-reactive
neutralizing antibodies against H5N1 by NT (H5pp) assay, but
none by HI assay (Figure 2A and B). In general HI and NT
antibody titres against H5N1 did not increase significantly after
vaccination. However one subject in Group 3 developed marked
increased HI (from,10 at baseline to 80) and NT (from 64 to 824)
after IIV boost of LAIV prime. A second subject in Group 4, who
had a baseline cross-reactive NT titre of 98, did not develop
increased NT or HI titres after IIV prime.
At baseline, serum cross-reacting antibodies by NI assay against
H5N1 were found in 15 (58%) subjects (Figure 1C). IIV, as prime
or boost significantly increased GMT to H5N1 compared to
baseline amongst subjects in heterologous prime boost Group 3
(from 206 to 544, 2.6-fold increase, p = 0.04) and non-significantly
in heterologous prime boost Group 4 (from 213 to 594, 2.8-fold
increase, p = 0.09) and in Group 2 following the first dose of
Figure 1. CONSORT (2010) flow diagram.
doi:10.1371/journal.pone.0059674.g001
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vaccine (from 139 to 315, 2.3-fold increase, p= 0.3). Similar
increases were not observed following LAIV.
All serum samples showed reactivity to H5N1 M2e (A/
Vietnam/1203/04) expressed on HEK 293 cell line at baseline.
However, following vaccination increased M2e binding was
negligible regardless of vaccination regimen (data not shown).
Purified nasal IgA from all subjects collected both before and after
vaccination showed no cross-neutralizing activity against H5N1
(data not shown).
2009 pH1N1.. At baseline 42% (11 of 26) subjects had pre-
existing cross-reactive antibodies to 2009 pH1N1 detected by HI
(range 10–40), and 27% (7 of 26) by NT (range 20–640) assays; of
these subjects, 8/11 (73%) and 6/7 (86%) gave a history of
previous seasonal influenza vaccination. Post-vaccination HI and
NT titre increases against 2009 pH1N1 were generally modest,
although an increase in NT titre was more common in subjects
with pre-existing cross-reactive antibodies (Figure 3A and B).
Single doses of IIV, given as prime (Groups 2 and 4), or as boost
(Group 3), were associated with an increase in HI titres for 5
subjects (Group 2: 2, Group 3: 1; Group 4: 2, respectively) and NT
titres for 3 subjects (Group 3: 1; Group 4: 2, respectively). Two of 8
subjects in Group 4 with pre-existing cross-reactive antibodies
developed both increased HI (10 to 20, and 20 to 80, respectively)
and NT (20 to 80, and 226 to 640, respectively) titres against 2009
pH1N1, after IIV prime.
Using NI, serum cross-reacting antibodies against 2009 pH1N1
were found in 35% subjects at baseline (Figure 3C). IIV, given as
prime or boost, significantly increased GMT to 2009 pH1N1
among subjects in Group 3 (from 107 to 244, 2.3-fold increase,
p = 0.007) and non-significantly in Groups 2 (from 96 to 193, 2.0-
fold increase, p = 0.4) and 4 (from 295 to 511, 1.7-fold increase,
p = 0.1). Purified nasal IgA from all subjects collected both before
and after vaccination showed no cross-neutralizing activity against
2009 pH1N1 (data not shown).
T-cell responses. The magnitude of the T-cell response,
defined as the combined frequency of IL-2, IFN-g and IL-2 plus
IFN-g producing T-cells is shown in Figure 4. Regardless of
vaccination schedule, priming with LAIV or IIV induced specific
T-cell responses against IIV antigens in about 80% subjects as
demonstrated by an increase of cytokine producing CD4+ T-cells,
ranging from 2–9 fold. Boosting with either LAIV or IIV failed to
further increase the CD4+ T-cell response.
Cross-reactive T-cell responses were assessed after in vitro
stimulation with peptide pools generated from nucleoprotein
(NP) of 2009 pH1N1 or H5N1 (A/Viet Nam/1194/2004)
(Figure 4B and C). Approximately 40% subjects demonstrated
increased cross-reactive CD4+ T-cell responses to NP of 2009
pH1N1 and to H5N1. However, these responses were less robust
than those directed against IIV antigens. A negligible recall CD8+
Table 1. Baseline characteristics in 26 healthy subjects, n (%).
Group 1 LAIV-
LAIV Group 2 IIV-IIV
Group 3 LAIV-
IIV
Group 4 IIV-
LAIV
Overall n (% of
total)
Number of subjects 5 5 8 8 26
Male:female 4:1 1:4 2:6 2:6 9:17 (35:65)
Caucasian 4 5 7 8 24 (92)
Age, years, median (IQR) 38 (1.4) 48 (4.5) 43 (7.7) 33 (6.7) 40 (13.8)
Age range, years
#30 1 0 1 4 6 (23)
31–40 3 0 2 3 8 (31)
41–49 1 5 5 1 12 (46)
No. of previous seasonal influenza vaccinations, median (IQR) 8 (9) 14 (10) 9 (9) 10 (14) 10 (10)
No. of previous seasonal influenza vaccinations
0 0 1 1 5 7 (27)
1–5 2 1 1 1 5 (19)
6–10 1 0 3 1 5 (19)
.10 2 3 2 1 8 (31)
Yes, but number unknown 0 0 1 0 1 (4)
Received LAIV previously 1 2 0 1 4/19 (21)
Years since last influenza vaccination
# 2 0 0 0 0 0
$ 3 5 4 6 3 18 (69)
Unknown 0 0 1 0 1 (4)
Cross-reactive antibodies present at baseline*
Against H5N1 3 2 5 5 15 (58)
Against pandemic H1N1 2009 0 1 1 7 9 (35)
Against both H5A1 and pandemic H1N1 2009 1 2 3 5 11 (42)
None against H5N1 or pandemic H1N1 2009 1 2 3 1 7 (27)
LAIV = live attenuated influenza vaccine; IIV = inactivated influenza vaccination; * as assessed by haemagglutination inhibition, neutralization and neuraminidase
inhibition assays.
doi:10.1371/journal.pone.0059674.t001
Cross-Reactivity after Seasonal Influenza Vaccine
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T-cell response was observed after in vitro stimulation with IIV
antigens or NP peptide pool (data not shown).
Safety and tolerability
All vaccine doses were well tolerated, there were no serious
adverse events, and no subject had to discontinue study participa-
tion early. Thirteen subjects received LAIV and 13 received IIV as
Dose 1: six and 10 respectively reported 52 AEs that were
considered probably or definitely related to vaccine (Table 2).
Overall 168 AEs were reported during the 4-week period following
Dose 1, and 171 during the same period after Dose 2.
After Dose 2 there was no obvious increase in frequency of
occurrence of AEs. Two of the 5 subjects who received 2 doses of
IIV (Group 2) complained of more severe pain at the injection site
following Dose 2 than following Dose 1 even though Dose 2 was
administered into the other arm. The two heterologous prime
boost regimens were not associated with any excess of reported
AEs compared to the homologous prime boost regimens although
the numbers in all groups are very small. There were no serious
adverse events (SAEs) reported in this trial.
Discussion
This is the first prospective study in humans to test the
hypothesis that prime boost regimens of seasonal influenza vaccine
can be used to elicit production of sub-heterotypic antibodies. Our
findings show that both homologous and heterologous prime boost
immunization did not enhance serum HI and NT titres to 2009
pH1N1 and avian H5N1 as compared to a single dose of vaccine.
Interestingly the increase of NT titres to both viruses was observed
in subjects who had pre-existing cross-reactive antibodies at
baseline; this supports previously reported findings [19]. The
observations provide more evidence that generation of cross-
reactive antibodies are derived from activation of cross-reactive
memory B-cells that recognize conserved epitopes in multiple
influenza strains [20] [21]. However, this type of immunological
response seems to be sporadic and may be influenced by genetic
and/or viral factors. Several additional subjects, including one
with a high baseline H5pp response, failed to enhance antibody
titres further following seasonal vaccination. More work is needed
Figure 2. Individual and geometric mean serum haemagglutination inhibition assay, H5pp assay and serum neuraminidase
inhibition assay results against avian H5N1 virus in 26 healthy human volunteers measured at baseline and two weeks following
each dose of prime boost seasonal influenza vaccination (2 doses administered 8 weeks apart).
doi:10.1371/journal.pone.0059674.g002
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to understand the complex factors involved in generation of cross-
reactive antibody responses in given individuals.
Unlike IIV, LAIV induced modest serum antibody responses in
all subjects regardless of whether LAIV was used as a prime or as a
boost. These observations are in line with previous reports, which
demonstrated modest serum HI titres after LAIV nasal vaccina-
tion [3] [22]. The biological mechanisms for protective immunity
elicited by LAIV are believed to involve a local immune response
in the lung via mucosal antibodies and T-cell responses [3]. Recent
reports have suggested a role for memory B cells localised to the
lung conferring protection against disease [23].
Neuraminidase activity is required for the release of newly
budded virus from the infected cell surface. Studies in humans
suggest that antibody to influenza neuraminidase is associated with
resistance to clinical disease [24] [25]. In this study, serum NI titres
against H5N1 and 2009 pH1N1 increased significantly in
heterologous prime boost Group 3 (LAIV-IIV). However, it would
be premature to draw conclusions from this since the sample size
in this study was very small and more subjects in this group had
detectable antibodies at baseline than in other groups.
Our findings confirm the efficacy of single dose trivalent
seasonal influenza vaccine in conferring robust antibody responses
against vaccine viruses in healthy adults. The addition of a second
(booster) dose in either homologous regimen (Groups 1 and 2)
conferred no demonstrable benefit. Reassuringly the addition of
the second dose had no impact on adverse event reporting in this
group of healthy adults. The only observation of note was that 2 of
5 subjects in Group 2 complained of more intense pain following
the second dose of IIV. A similar finding was observed in a study
of healthy children aged 5–8 years [26] where a significantly
higher proportion of subjects reported pain following the second
dose. Both prime boost regimens were also well tolerated with no
excess of AEs after the second dose, including IIV given as Dose 2.
Both IIV and LAIV elicited recall CD4+ T-cell responses
against vaccine antigens as detected by ICS staining of IFN-g and
IL-2. In agreement with previous findings [19] [27] [28] [29] we
detected pre-existing cross-reactive CD4+ T-cells specific to NP
derived from 2009 pH1N1 and H5N1. The increases in cross-
reactive T-cell responses were observed in some subjects but the
prime boost vaccination regimen did not appear to result in
Figure 3. Individual and geometric mean serum haemagglutination inhibition assay, microneutralization assay and serum
neuraminidase inhibition assay results against pandemic H1N1 2009 virus in 26 healthy human volunteers measured at baseline
and two weeks following each dose of prime boost seasonal influenza vaccination (2 doses administered 8 weeks apart).
doi:10.1371/journal.pone.0059674.g003
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superior cross-reactive T- cell responses. Unlike in the mouse
model [30] [31] [32] the role of cross-reactive T-cells in protecting
against influenza has not been well described in humans. A recent
human challenge study with influenza demonstrated that pre-
existing CD4+ T-cell responses to conserved NP and matrix
protein could reduce severe illness in the absence of specific
antibodies [33]. One could speculate that cross-reactive T-cells
may mediate heterosubtypic immunity in humans as well. Further
studies are required to support this hypothesis.
This study was a pilot feasibility study and as such had a
number of important limitations. Firstly the sample sizes are small
and therefore unlikely to detect subtle trends or immunological
responses generated in just a small proportion of subjects. The
small size was off-set by having a relatively highly vaccinated
group of subjects, with a high proportion of females, both of which
were considered to increase the chances that favourable immu-
nological responses would be observed [34] [35]. Secondly the
study took place during the initial stages of the 2009 H1N1
influenza pandemic, which had just reached Bangkok at the time
the study commenced. Although none of the subjects developing
cross-protective responses to pH1N1 2009 during the course of the
study gave a history of influenza-like illness, it remains a possibility
that the observed responses against pH1N1 2009 were in fact
influenced by in vivo exposure to natural disease. Even if this is the
case, it cannot explain the robust serum antibody response to
H5N1 observed in the single subject from Group 3. Finally the
lack of good correlates of protection generated by LAIV discussed
above may mean that we missed a cross-protective effect afforded
by this vaccine given either as prime or boost.
Despite the fact that broad immune responses indicating
significant cross-protection against pH1N1 2009 and avian
H5N1 influenza viruses were not observed in the majority of
prime boost recipients, in vitro cross-protection against one or other
virus assessed by HI and/or NT was observed in several
individuals; moreover most subjects developed detectable respons-
es on NI assay and some developed cross-reactive CD4+ T cell
responses against nucleoprotein, These results lend support to the
current recommendation for administration of seasonal influenza
Figure 4. Individual and geometric mean peripheral blood CD4+ T-cell responses measured at baseline, two weeks after dose 1 and
two weeks after dose 2, by study group: (A) against vaccine antigens in IIV, (B) against nucleoprotein H5N1, and (C) against
nucleoprotein pH1N1 2009.
doi:10.1371/journal.pone.0059674.g004
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vaccine at the outset of an influenza pandemic. Such a strategy
may afford some protection to a sub-set of individuals, particularly
those with a degree of pre-existing immunity. Our data support
the administration a single dose of trivalent seasonal vaccine to
those individuals at risk of disease who have not previously
received that season’s recommended seasonal influenza vaccine;
however, based on our preliminary findings we do not have
enough evidence to recommend administration of a second (prime
boost) dose. Even if progression to clinical or severe disease is
prevented in only a minority of recipients, seasonal influenza
vaccine administration at the outset of a pandemic could represent
a cost-effective public health strategy and buy valuable time while
a specific vaccine is being developed.
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